CareDx (NASDAQ:CDNA) Given “Neutral” Rating at HC Wainwright

CareDx (NASDAQ:CDNA)‘s stock had its “neutral” rating reissued by equities researchers at HC Wainwright in a research report issued on Tuesday,Benzinga reports. They presently have a $26.00 price objective on the stock. HC Wainwright’s price objective would suggest a potential upside of 3.71% from the stock’s previous close.

A number of other brokerages also recently weighed in on CDNA. BTIG Research reduced their target price on CareDx from $40.00 to $35.00 and set a “buy” rating on the stock in a report on Tuesday, November 5th. The Goldman Sachs Group boosted their price objective on CareDx from $26.00 to $35.00 and gave the stock a “buy” rating in a research report on Wednesday, October 16th. Finally, StockNews.com raised shares of CareDx from a “hold” rating to a “buy” rating in a research note on Thursday, October 17th. One research analyst has rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $29.00.

CareDx Stock Up 6.1 %

Shares of NASDAQ:CDNA opened at $25.07 on Tuesday. CareDx has a 12-month low of $7.42 and a 12-month high of $34.84. The company’s 50 day moving average price is $23.01 and its two-hundred day moving average price is $24.40. The firm has a market cap of $1.34 billion, a PE ratio of -9.29 and a beta of 1.86.

CareDx (NASDAQ:CDNA) last announced its quarterly earnings data on Monday, November 4th. The company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.11. CareDx had a negative return on equity of 53.70% and a negative net margin of 45.90%. The firm had revenue of $82.88 million during the quarter, compared to analysts’ expectations of $80.04 million. During the same period in the previous year, the firm earned ($0.43) EPS. The company’s quarterly revenue was up 23.4% compared to the same quarter last year. On average, research analysts expect that CareDx will post -0.7 EPS for the current year.

Insider Activity at CareDx

In related news, Director Peter Maag sold 5,000 shares of CareDx stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $25.00, for a total value of $125,000.00. Following the completion of the sale, the director now owns 330,024 shares of the company’s stock, valued at approximately $8,250,600. This trade represents a 1.49 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 4.90% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On CareDx

Institutional investors have recently bought and sold shares of the stock. Renaissance Technologies LLC grew its position in CareDx by 6.2% during the second quarter. Renaissance Technologies LLC now owns 1,512,700 shares of the company’s stock valued at $23,492,000 after buying an additional 88,100 shares during the period. Allspring Global Investments Holdings LLC lifted its stake in CareDx by 868.6% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 204,987 shares of the company’s stock worth $6,401,000 after purchasing an additional 183,823 shares in the last quarter. Virtue Capital Management LLC bought a new stake in CareDx during the third quarter valued at $755,000. Driehaus Capital Management LLC bought a new stake in shares of CareDx during the 2nd quarter valued at about $2,852,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new position in shares of CareDx in the 3rd quarter worth $1,671,000.

About CareDx

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.